Using patient-derived cancer models to address health disparities in cancer treatment
Official title: University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
Run by University of California, Davis · NCT04410302 · Data updated 2026-11-12
This study is trying to create and test cancer models from patients, especially those from minority backgrounds, to see how we can improve cancer treatments for bladder, gastric, liver, and lung cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years to 100 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University of California, Davis Academic / other |
| Locations | 2 sites (Orange, California and 1 other locations) |
| Status | Recruiting |
| Started | November 12, 2019 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT04410302 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients currently receiving treatment for bladder, gastric, liver, or lung cancers who can provide informed consent.
✕Probably not a fit
Patients who are not receiving treatment for the specified cancers or who are unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to develop and characterize over 200 patient-derived xenografts (PDXs) to investigate cancer health disparities affecting racial and ethnic minorities. The focus is on bladder, gastric, liver, and lung cancers, with a significant portion of PDXs derived from minority patients, particularly Hispanic/Latino Americans, African Americans, and Asian American/Native Hawaiians/Pacific Islanders. The study will utilize these PDXs for preclinical testing of various drug treatments to enhance precision medicine approaches tailored to these populations. Collaborations with the National Cancer Institute and other centers will support the research objectives.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized cancer treatments for underrepresented racial and ethnic groups.
How similar studies have gone: Other studies have shown promise in using patient-derived xenografts to improve cancer treatment outcomes, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer) * Signed informed consent that will be put on file Exclusion Criteria: * No informed consent obtained * Specimen unacceptable/degraded/etc. * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Adults unable to consent
Where it's running
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States Recruiting -
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States Recruiting
Study contacts
- Principal investigator: Luis G Carvajal-Carmona — University of California, Davis
- Study coordinator: Asst. Clinical Research Coordinator
- Email: tfle@ucdavis.edu
- Phone: 916-734-1587
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Vanguard: a new blood test approach to screen for multiple cancers
This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.
-
Imaging study using two antibody fragments in patients with solid tumors
This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.